Active, not recruitingPhase 2NCT04230499
Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
Studying Familial adenomatous polyposis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rapamycin Holdings Inc.
- Principal Investigator
- George E Peoples, MD, D.M.DSponsor CMO
- Intervention
- Encapsulated Rapamycin (eRapa)(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (4)
- Michigan Medicine, Ann Arbor, Michigan, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Ohio State University, Columbus, Ohio, United States
- UT Health, San Antonio, Texas, United States
Collaborators
Cancer Insight, LLC · Biodexa Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04230499 on ClinicalTrials.govOther trials for Familial adenomatous polyposis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06641310Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)University of Michigan Rogel Cancer Center
- RECRUITINGPHASE1NCT05630794Testing for Safety and Colorectal Cancer Preventive Effects of ONC201National Cancer Institute (NCI)
- RECRUITINGPHASE3NCT06950385Phase 3 Trial of eRapa in Patients With Familial Adenomatous PolyposisRapamycin Holdings Inc.
- RECRUITINGNANCT06538402Ten Versus Fifteen Centimeter Pouch in IPAA SurgeryOdense University Hospital
- RECRUITINGNCT06614738Microbial and Environmental Factors Associated with Polyps Development in Familial Adenomatous Polyposis (MicrobEnvironment in FAP)Hospices Civils de Lyon
- RECRUITINGNANCT06578637Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous PolyposisAbramson Cancer Center at Penn Medicine
- RECRUITINGPHASE3NCT06545526Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous PolyposisYonsei University
- ACTIVE NOT RECRUITINGNCT07461246Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano